Lack of Epstein–Barr virus infection in Chinese myasthenia gravis patients
Article first published online: 14 MAY 2013
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Acta Neurologica Scandinavica
Volume 128, Issue 5, pages 345–350, November 2013
How to Cite
Lack of Epstein–Barr virus infection in Chinese myasthenia gravis patients. Acta Neurol Scand 2013: 128: 345–350. © 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd., , , , , , , .
- Issue published online: 7 OCT 2013
- Article first published online: 14 MAY 2013
- Manuscript Accepted: 11 FEB 2013
- Chinese PLA Postgraduate Medical School
- myasthenia gravis;
- Epstein–Barr virus
There are three recent contradictory reports on the incidence of Epstein–Barr virus in the pathogenesis of myasthenia gravis, with all studies carried out in Caucasian patients. The current study evaluated whether Epstein–Barr virus infection had a role in the pathogenesis of myasthenia gravis in a cohort of 30 Chinese patients.
Materials and methods
Serial paraffin sections of thymic hyperplasia obtained from myasthenia gravis patients were analyzed for the presence of Epstein–Barr virus-encoded small RNA -1 and Epstein–Barr virus latent membrane protein 1 by in situ hybridization and immunohistochemistry, respectively. Epstein–Barr virus+ cervical lymph nodes from lymphoma patients and Epstein–Barr virus- thymus specimens obtained during cardiac surgery served as the positive and negative control groups, respectively.
All the 30 myasthenia gravis specimens were negative for both Epstein–Barr virus-encoded small RNA -1 and Epstein–Barr virus latent membrane protein 1 tests. However, we obtained well-characterized membrane and cytoplasmic immunohistochemical and in situ hybridization staining for both Epstein–Barr virus latent membrane protein 1 and Epstein–Barr virus-encoded small RNA -1, respectively, in the positive control samples.
Our results therefore do not support a role of thymic Epstein–Barr virus infection in myasthenia gravis pathogenesis and calls for an integration of methodological and interpretation issues in detecting Epstein–Barr virus incidence in myasthenia gravis patients.